Alder Biopharma Cmn (NASDAQ:ALDR) shares traded -8.29% down during most recent session to reach at the closing price of $8.85. The stock exchanged hands 2.19 Million shares versus average trading capacity of 1.75 Million shares, yielding a market cap of $606.49 Million. Wall Street analysts covering the stock are projecting that the stock will reach $35.44 within the next 52-weeks. The mean target projections are based on 9 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Alder Biopharma Cmn (NASDAQ:ALDR) high price target of $51 and with a conservative view have low price target of $9.

BMO Capital “Maintained” Alder Biopharma Cmn (NASDAQ:ALDR) in a research note issued to investors on 8/10/17 to Outperform with price target of $27.

Additionally on 8/09/17 BMO Capital “Maintained” Alder Biopharma Cmn (NASDAQ:ALDR) to Outperform setting price target at $27 and on 5/16/17 Needham “Initiates Coverage On” the stock to Buy at $36. Furthermore on 5/05/17 UBS “Initiates Coverage On” the stock to Sell at $13.

On the other hand the company has Relative Strength Index (RSI 14) of 29.07 along with Average True Range (ATR 14) of 0.72, Consequently Alder Biopharma Cmn (NASDAQ:ALDR)’s weekly and monthly volatility is 6.47%, 6.50% respectively. The company’s beta value is at 0.

In terms of Buy, Sell or Hold recommendations, Alder Biopharma Cmn (NASDAQ:ALDR) has analysts’ mean recommendation of 2.1. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Alder Biopharma Cmn (NASDAQ:ALDR)’s minimum EPS for the current quarter is at $-1.97 and can go high up to $-1.06. The consensus mean EPS for the current quarter is at $-1.37 derived from a total of 9 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.7 earnings per share for the same quarter during last year.

Previously Alder Biopharma Cmn (NASDAQ:ALDR) reported $-1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $-1.61 by $0.13. The company posted an earnings surprise of 8.1%.

Currently Alder Biopharma Cmn (NASDAQ:ALDR)’s shares owned by insiders are 0.2%, whereas shares owned by institutional owners are 93.4%. However the six-month change in the insider ownership was recorded -0.43%, as well as three-month change in the institutional ownership was recorded 1.71%.

Alder Biopharma Cmn (NASDAQ:ALDR) 52-week high price stands at $36.48 and low price stands at $9.15, its price distance from 52-week high is -75.74% while its distance from 52-week low price is -3.28%. The stock hit its 52-week high on 08/24/16, and 52-week low on 08/10/17.

Alder Biopharma Cmn (NASDAQ:ALDR)’s trailing twelve month revenues are $100000, whereas its price to sales ratio for the same period is 6064.91. Its book value per share for the most recent quarter is $5.71 while its price to book ratio for the same period is 1.55, as for as the company’s cash per share for the most recent quarter is $4.23, however its price to cash per share ratio for the same period is 2.09. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.